For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue-Revenue | - | - | - | 0 |
| Total revenue-Other Revenue | - | - | - | 0 |
| Total revenue | - | -45,000* | 90,000 | 0 |
| Research and development, net of reimbursements | 4,201,000 | 7,433,500* | 4,248,000 | 4,879,000 |
| General and administrative | 1,702,000 | 8,976,000* | 1,534,000 | 2,624,000 |
| Total operating expenses | 5,903,000 | 16,409,500* | 5,782,000 | 7,503,000 |
| Loss from operations | -5,903,000 | -16,454,500* | -5,692,000 | -7,503,000 |
| Interest income - net | 381,000 | 581,000 | 561,000 | 625,000 |
| Total other income | 381,000 | 581,000* | 561,000 | 625,000 |
| Net loss | -5,522,000 | -15,873,500 | -5,131,000 | -6,878,000 |
| Basic EPS | -0.18 | -0.509 | -0.16 | -0.22 |
| Diluted EPS | -0.18 | -0.509 | -0.16 | -0.22 |
| Basic Average Shares | 31,237,681 | 31,195,891 | 31,195,891 | 31,195,891 |
| Diluted Average Shares | 31,237,681 | 31,195,891 | 31,195,891 | 31,195,891 |
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM)